| Followers | 141 |
| Posts | 5785 |
| Boards Moderated | 0 |
| Alias Born | 06/09/2020 |
Thursday, December 28, 2023 3:30:36 PM
https://www.cmcmarkets.com/en/opto/ken-griffin-among-worlds-richest-after-stellar-year-for-citadel
Laura Posner, a partner with the law firm representing Northwest, insisted the “hard data” would vindicate her client’s case, adding “It’s hard to dispute actual transactions and patterns.”
And how about read what is posted for your viewing pleasure? Posner addressed Citadel in this piece countless times
https://www.lawdragon.com/lawyer-limelights/2023-06-07-laura-posner-is-leading-the-way-in-investor-protection
And in it, she indirectly states who she is fighting for and against.
LD: What’s professionally satisfying about your work?
LP: At the end of the day, for me it’s still about wanting to help those in need. My shareholder derivative cases have helped investors transform companies into safer environments for their employees. My securities fraud class action cases have helped investors – teachers, fireman, police, union workers and other state employees – recover the essential retirement money they lost due to a company’s fraud.
I went into law with an interest in civil rights work, and I think my work in securities class actions and shareholder derivative litigation tracks closely to my initial goal. My team and I are fighting for the underdog. We are helping people protect their investments and helping keep the marketplace fair.
I get to help public employees and unions – the critical backbone of this country – who are dependent on their pensions and return money back to their pockets so that they can have a secure retirement.
As the wife of an educator, the significance of my work hits close to home too. It’s incredibly gratifying to do what I do.
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
